Exciting Developments for NLS Pharmaceutics and Kadimastem
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. (TASE: KDST) have announced significant advancements regarding their proposed merger. This merger presents a unique opportunity for both companies to enhance their positions in the biopharmaceutical marketplace, focusing on innovative therapies aimed at treating central nervous system disorders and neurodegenerative diseases.
Understanding the Merger Dynamics
The announcement reveals that all essential conditions precedent for the merger have either been fulfilled or waived by the involved parties. With Nasdaq's approval for NLS Pharmaceutics, both companies are prepared for the next steps leading up to the merger, making it a historical point for their operations.
Timeline and Key Dates
The merger is strategically planned for completion on October 30, 2025, a date that marks a transformative moment for NLS and Kadimastem. Following this, Kadimastem’s ordinary shares will be delisted from the Tel Aviv Stock Exchange, with trading suspended until the merger is finalized. This step illustrates the companies’ commitment to streamline their operations and focus on the successful integration of their respective business models.
New Stock Symbol and Share Exchange Ratio
Upon completing the merger, the newly formed company will operate under the name NewCelX Ltd., with its common shares listed on the Nasdaq Capital Market under the symbol "NCEL." This name change coincides with a pivotal exchange ratio established at 7.06 NLS common shares for each Kadimastem ordinary share. After a reverse share split of NLS’s common shares, the final ratio will rest at 0.706 NLS common shares per Kadimastem ordinary share.
Trading Availability and Transition
Shareholders can expect the new common shares, previously NLS common shares, to be deposited into their accounts following market hours on November 3, 2025. Trading for these shares on the Nasdaq is slated to commence on November 4, 2025. This transition is crucial for ensuring that shareholders are integrated into the new corporate structure smoothly. As the merger progresses, both companies are committed to keeping their shareholders informed of any developments.
About NLS Pharmaceutics
NLS Pharmaceutics Ltd. specializes in creating groundbreaking therapies for neurological disorders. With a robust pipeline and strong commitment to innovation, NLS is well-positioned to address unmet medical needs in the clinical landscape. Their detailed focus on CNS disorders showcases their dedication to advancing healthcare solutions that can significantly improve patient lives.
About Kadimastem
Kadimastem Ltd. stands at the forefront of cell therapy innovation, developing off-the-shelf cell products specifically targeting neurodegenerative diseases and diabetes. Their approach emphasizes accessibility and efficacy, making strides toward effective treatment options for patients suffering from chronic conditions.
Social Media Presence
Both companies maintain active engagement on various social platforms, ensuring they keep their followers updated. Interested parties can find NLS Pharmaceutics on LinkedIn and Kadimastem on multiple platforms including Facebook and Instagram, promoting transparency and accessibility in communication.
Frequently Asked Questions
What is the date of the merger completion?
The merger is set to be completed on October 30, 2025.
What will be the new name of the combined company?
The combined company will be called NewCelX Ltd.
What trading symbol will the new company use?
The new company will be listed under the ticker symbol "NCEL" on the Nasdaq Capital Market.
What is the exchange ratio for the shares?
The final exchange ratio is set at 0.706 NLS common shares for each Kadimastem ordinary share.
How will shareholders receive their new shares?
New shares are expected to be deposited into Kadimastem shareholders' accounts after trading hours on November 3, 2025.
